Topical Copper Chlorin Composition for Actinic Keratosis Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for actinic keratosis suffer from incomplete clearance, high recurrence rates, and severe treatment-related adverse reactions, particularly with field-directed therapies, and there is a need for new therapies that address these issues.
Innovation Solution
Compositions and methods utilizing chlorin compounds, particularly copper chlorin compounds, for topical treatment and prevention of actinic keratosis, which include safe and effective concentrations of copper chlorin in various forms and carriers for application to affected areas, potentially combined with other antiviral agents to enhance penetration and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Area of stationary object
If field-directed topical treatments are used for actinic keratosis, then treatment coverage area is improved, but treatment-related adverse reactions worsen
Solution Approach 1:
The patent uses 5-aminolevulinic acid (ALA) as an intermediary substance that is topically applied to the skin. ALA serves as a prodrug that is converted endogenously into protoporphyrin IX, which then acts as the actual photosensitizing agent during PDT. This intermediary approach allows for selective accumulation in actinic keratosis lesions, enabling field-directed treatment while minimizing adverse reactions through targeted activation only in affected areas.
Solution Approach 2:
The patent implements local quality by creating differential treatment effects between healthy and diseased skin. ALA preferentially accumulates in actinic keratosis lesions due to altered cellular metabolism and permeability, allowing the photosensitizing agent to be concentrated where needed. During PDT, light activation produces reactive oxygen species selectively in the lesion areas, treating the disease while sparing surrounding healthy tissue from adverse effects.
2Area of stationary object
If current field-directed therapies are used for actinic keratosis, then treatment coverage is improved, but recurrence rates worsen
Solution Approach 1:
The patent implements continuity of useful action through a multi-step treatment protocol that ensures complete eradication of actinic keratosis. The process involves: (1) topical application of ALA that continuously accumulates in lesions over several hours, (2) development of protoporphyrin IX that provides sustained photosensitization, and (3) PDT treatment that delivers continuous cytotoxic effect during light exposure. This continuous action sequence prevents incomplete treatment and reduces recurrence by ensuring complete destruction of abnormal cells throughout the treated field.
Solution Approach 2:
The patent utilizes parameter changes in the biochemical state of the treatment agent. ALA is applied in a non-toxic form that can be safely applied to large skin areas. Through endogenous metabolic conversion, it transforms into protoporphyrin IX, which has dramatically different properties - highly photosensitive and cytotoxic when activated by specific light wavelengths. This parameter change from a safe prodrug to an active photosensitizer enables effective field treatment with controlled therapeutic effect and minimal recurrence.
3Manufacturing precision
If cryotherapy is used for actinic keratosis, then lesion clearance is improved, but pain and inflammation worsen
Solution Approach 1:
The patent replaces the mechanical cryotherapy system (liquid nitrogen freezing) with a photochemical system. Instead of using extreme cold temperatures to destroy lesions, the invention uses photosensitized chemical reactions. ALA is converted to protoporphyrin IX, which when activated by red light (630-690 nm), generates reactive oxygen species that chemically destroy actinic keratosis cells. This substitution eliminates the mechanical trauma, pain, and inflammation associated with cryotherapy while maintaining effective lesion clearance.
Solution Approach 2:
The patent changes the physical parameters of the treatment from extreme temperatures to optical wavelengths. Cryotherapy uses temperatures below -196°C (liquid nitrogen), causing thermal damage, pain, and inflammation. The patent instead uses red light wavelengths (630-690 nm) that are well-tolerated by skin, combined with photosensitized chemical reactions that produce localized cytotoxic effects. This parameter change from thermal to photochemical treatment eliminates pain and inflammation while achieving precise lesion clearance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The copper chlorin compositions demonstrate higher clearance rates of actinic keratosis lesions with reduced recurrence and minimal adverse effects, providing anti-viral impact to eliminate HPV-infected lesions and prevent reoccurrence.
Implementation Method 1
The AK growths are more common in fair-skinned people and those who are frequently in the sun. They occur when skin gets damaged by UV radiation from the sun or indoor tanning beds
Implementation Method 2
Compositions and methods utilizing chlorin compounds, particularly copper chlorin compounds, for topical treatment and prevention of actinic keratosis
Data Source
AI summary
Treatment compositions and methods for treating and/or preventing actinic keratosis comprising applying a chlorin treatment composition in a topical form to one or more actinic keratosis lesions. A treatment composition preferably comprises a copper chlorin, such as a sodium copper chlorophyllin complex, trisodium copper chlorin p6, disodium copper isochlorin e4, or trisodium copper chlorin e6. A treatment composition comprises around 0.002% to around 0.1% by weight of copper chlorin. Treatments disclosed herein may result in elimination of the actinic keratosis lesions.